A drug used to treat Type 2 diabetes and obesity could also slow down the process of ageing, researchers believe.
Semaglutide, better known as Ozempic, "has far-reaching benefits beyond what we initially imagined," Prof Harlan Krumholz, from the Yale School of Medicine, said following the publication of several new studies.
They found that the drug could be used to treat a wide range of illnesses linked to heart failure, arthritis, Alzheimer's and even cancer.
The new data has been published in a number of medical journals, including the Journal of the American College of Cardiology (JACC), which Prof Krumholz edits.
Subscribe here: http://bit.ly/1rbfUog
For more news, analysis and features visit: www.bbc.com/news
#Ozempic #BBCNews
(novo nordisk is the patent holder for semaglutide and also sponsored the trials as a whole)
But on the other hand I wasn’t thinking clearly, horses are an existing factor that correlate with wealth. This being a pre-market, double blind trial, with a placebo group selected from the same pool of people as those that actually got the semaglutide, that isn’t a factor here.
If it was just an observational study across wider populations they’d have to try to control for a lot more factors
I think that would depend on the funding source
https://www.sciencedirect.com/science/article/pii/S0735109724081567
(novo nordisk is the patent holder for semaglutide and also sponsored the trials as a whole)
But on the other hand I wasn’t thinking clearly, horses are an existing factor that correlate with wealth. This being a pre-market, double blind trial, with a placebo group selected from the same pool of people as those that actually got the semaglutide, that isn’t a factor here.
If it was just an observational study across wider populations they’d have to try to control for a lot more factors